000310364 001__ 310364
000310364 005__ 20260311121052.0
000310364 0247_ $$2doi$$a10.1002/hem3.70306
000310364 0247_ $$2pmid$$apmid:41799248
000310364 0247_ $$2pmc$$apmc:PMC12961523
000310364 037__ $$aDKFZ-2026-00560
000310364 041__ $$aEnglish
000310364 082__ $$a610
000310364 1001_ $$00000-0001-7674-2148$$aPennings, Elise R A$$b0
000310364 245__ $$aThe European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.
000310364 260__ $$aHoboken$$bJohn Wiley & Sons Ltd.$$c2026
000310364 3367_ $$2DRIVER$$aarticle
000310364 3367_ $$2DataCite$$aOutput Types/Journal article
000310364 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773226636_3298571
000310364 3367_ $$2BibTeX$$aARTICLE
000310364 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310364 3367_ $$00$$2EndNote$$aJournal Article
000310364 500__ $$a#NCTZFB9#
000310364 520__ $$aDespite its great promise, implementation of CAR-T therapy-a personalized, logistically complex, and expensive treatment-remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU-approved) for 15 hematologic malignancy indications. To better understand patient access to EU-approved commercial CAR-T therapy, we evaluated the current status in all 30 countries where EU-approval is valid plus the UK, addressing economic, clinical, and organizational aspects, and identifying challenges and strategies for improvement. A two-step approach was used, complementing data from marketing authorization holders (4/4 responded) with country-specific insights from clinical experts obtained via an online survey (30/31 responded). In August 2024, 26% of the 31 countries had no CAR-T products commercially available, 74% ≥ 1 product for non-Hodgkin lymphoma and leukemia, and 16% ≥ 1 product for multiple myeloma. One-time payment was the most used reimbursement method. Time to access varied significantly, with medians ranging from 0 (France/Germany) to 53 months (Slovakia). The median number of qualified CAR-T centers per 10 million population per country was 5.0 (IQR: 3.0-6.1). In most countries, patient eligibility assessment was decentralized. Costs and logistical complexity were main factors restricting access in countries with and without commercially available products. Proposed solutions included cost reductions, improving reimbursement processes, and increasing healthcare resources. This study shows that patient access to commercial CAR-T therapy in Europe remains limited. Its insights into this multi-faceted problem can guide policy-making, advocacy work, and research to make this transformative treatment accessible to more patients in need.
000310364 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000310364 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310364 7001_ $$aThielen, Frederick W$$b1
000310364 7001_ $$aBroussais, Florence$$b2
000310364 7001_ $$00000-0002-5157-4376$$aDelgado, Julio$$b3
000310364 7001_ $$aJaeger, Ulrich$$b4
000310364 7001_ $$aSanges, Carmen$$b5
000310364 7001_ $$aCabrerizo, Yolanda$$b6
000310364 7001_ $$aRoux-Opstaele, Lutgart$$b7
000310364 7001_ $$aDreuillet, Caroline$$b8
000310364 7001_ $$aGonzalez-Marcano, Eglys$$b9
000310364 7001_ $$aMillán, Olga$$b10
000310364 7001_ $$aHuber, Barbara$$b11
000310364 7001_ $$aClavreul, Solène$$b12
000310364 7001_ $$aBolaños, Natacha$$b13
000310364 7001_ $$aNier, Samantha$$b14
000310364 7001_ $$aMihályová, Jana$$b15
000310364 7001_ $$aHájek, Roman$$b16
000310364 7001_ $$aHorňáková, Michaela$$b17
000310364 7001_ $$aDoeswijk, Robin$$b18
000310364 7001_ $$aThieblemont, Catherine$$b19
000310364 7001_ $$0P:(DE-HGF)0$$aHudecek, Michael$$b20
000310364 7001_ $$aUyl-de Groot, Carin A$$b21
000310364 7001_ $$00000-0002-8904-3802$$aKersten, Marie José$$b22
000310364 773__ $$0PERI:(DE-600)2922183-3$$a10.1002/hem3.70306$$gVol. 10, no. 3, p. e70306$$n3$$pe70306$$tHemaSphere$$v10$$x2572-9241$$y2026
000310364 909CO $$ooai:inrepo02.dkfz.de:310364$$pVDB
000310364 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000310364 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000310364 9141_ $$y2026
000310364 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-06$$wger
000310364 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMASPHERE : 2022$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-26T06:26:50Z
000310364 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-26T06:26:50Z
000310364 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2024-08-26T06:26:50Z
000310364 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bHEMASPHERE : 2022$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-06
000310364 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-06
000310364 9201_ $$0I:(DE-He78)WA01-20160331$$kWA01$$lKoordinierungsstelle NCT WERA$$x0
000310364 980__ $$ajournal
000310364 980__ $$aVDB
000310364 980__ $$aI:(DE-He78)WA01-20160331
000310364 980__ $$aUNRESTRICTED